BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11327536)

  • 21. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
    Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
    Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy.
    Glaspy JA
    Bone Marrow Transplant; 1999 May; 23 Suppl 2():S21-7. PubMed ID: 10335873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful engraftment by sparing primitive and committed hematopoietic progenitors.
    Almici C; Ferremi P; Lanfranchi A; Ferrari E; Verardi R; Marini M; Rossi G
    Haematologica; 2003 Dec; 88(12):1390-5. PubMed ID: 14687993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction: current issues in high-dose chemotherapy and stem cell support.
    Shea TC
    Bone Marrow Transplant; 1999 May; 23 Suppl 2():S1-5. PubMed ID: 10335870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
    Pedrazzoli P; Ponchio L; Zibera C; Da Prada GA; della Cuna GR
    Cancer; 1999 May; 85(10):2295-6. PubMed ID: 10326711
    [No Abstract]   [Full Text] [Related]  

  • 26. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [High dosage chemotherapy and peripheral blood stem cell transplantation in breast carcinoma].
    Jentsch-Ullrich K; Höffken HG; Franke A
    Zentralbl Chir; 1998; 123 Suppl 5():162-4. PubMed ID: 10063605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in various malignancies.
    Efremidis AP; Koumakis G; Filis J; Moraki M; Vassilomanolakis M; Barbounis V; Hatzichristou H; Papanastasiou K; Stamatellou M
    Bone Marrow Transplant; 1996 Apr; 17(4):673-4. PubMed ID: 8722374
    [No Abstract]   [Full Text] [Related]  

  • 32. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.
    Elias AD; Mazanet R; Wheeler C; Anderson K; Ayash L; Schwartz G; Tepler I; Pap S; Pelaez J; Hunt M
    Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S25-9. PubMed ID: 1687204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
    Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
    Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC).
    Cassens U; Momkvist PH; Zuehlsdorf M; Mohr M; Kienast J; Berdel WE; Sibrowski W
    Bone Marrow Transplant; 2001 Jul; 28(1):13-20. PubMed ID: 11498739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood.
    Prete A; Rosito P; Alvisi P; Rondelli R; Melchionda F; Magrini E; Pession A
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S21-3. PubMed ID: 9989884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
    Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
    Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.